CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04797767
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:09.437949+00:00
Published At: 2026-04-17T00:00:00+00:00
Record Updated At: 2026-04-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "Myeloid Neoplasm", "Relapsed Acute Biphenotypic Leukemia", "Relapsed Acute Myeloid Leukemia", "Relapsed Mixed Phenotype Acute Leukemia", "Relapsed Myeloid Neoplasm", "Refractory Acute Biphenotypic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Refractory Myeloid Neoplasm", "Recurrent Myeloid Sarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-17"
protocolSection.identificationModule.nctId: "NCT04797767"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.